Immune evasion in renal cell carcinoma: biology, clinical translation, future directions

Xiaoyang Wang, Robert Lopez, Rebecca Luchtel, Sassan Hafizi, Benjamin Gartrell, Niraj K. Shenoy*

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

77 Downloads (Pure)


Targeted therapies and immune checkpoint inhibitors have advanced the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade. While checkpoint inhibitors have demonstrated survival benefit and are currently approved in the front-line and second-line settings, primary and secondary resistance is common. A comprehensive understanding of the mechanisms of immune evasion in RCC is therefore critical to the development of effective combination treatment strategies. This article reviews the current understanding of the different, yet coordinated, mechanisms adopted by RCC cells to evade immune killing; summarizes various aspects of clinical translation thus far, including the currently registered RCC clinical trials exploring agents in combination with checkpoint inhibitors; and provides perspectives on the current landscape and future directions for the field.
Original languageEnglish
Pages (from-to)75-85
Number of pages11
JournalKidney International
Issue number1
Early online date16 Sept 2020
Publication statusPublished - 1 Jan 2021


  • biology
  • carcinoma, renal cell/drug therapy
  • forecasting
  • humans
  • immune evasion
  • immunotherapy
  • kidney neoplasms/drug therapy


Dive into the research topics of 'Immune evasion in renal cell carcinoma: biology, clinical translation, future directions'. Together they form a unique fingerprint.

Cite this